Here's why you should stick with your CSL Limited shares

For financial strength, earnings growth and business development, CSL Limited (ASX:CSL) is a leading performer among the big ASX companies and a strong long-term investment opportunity.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Biopharmaceutical CSL Limited (ASX: CSL) has been an Aussie success story for many years. It may even earn the bragging rights of being the first company in the S&P/ASX 200 Index (ASX: XJO) (Index: ^AXJO) to reach a $100 share price. It's about $94 currently and now ahead of Commonwealth Bank of Australia (ASX: CBA), which is around $92.

That won't make it a reason to buy the stock. However, I can give several reasons why the company is worth buying and holding for a long time. For financial strength, earnings growth and business development, it is a leading performer among the big ASX companies.

Balance sheet strength

First, take a look at the strong balance sheet. Its cash position rose to $1 billion as of December 2014, up from $608 million. It has taken on more long-term debt recently, yet the current level of $2.3 billion is less than 2 times more than its financial year 2014 earnings of $1.37 billion. With its cash and earnings capability, the company should have no problem with managing and paying its debt, making it financially rock-solid.

Earnings growth and profitability

Annual earnings per share (EPS) growth has been trending up for the past ten years, rising an average annual 21% for a solid performance. Its blood-related medical supplies like albumin and its viral and bacterial disease treatments are in high demand from healthcare providers.

In addition, these specialised products can command a premium price. Net profits are usually 20% – 24%, so this is no commodity-producer business. That gives the company protective "moats" around its business against competition.

                          CSL Limited     Annual earnings per share  10-year chart

csl eps chart

    Data from Morningstar

Growing world-class business

CSL is the largest ASX-listed biopharmaceutical company in Australia, but in the last 5-10 years its overseas business has grown dramatically. About 90% of its revenue is generated internationally, with its single biggest market being the US.

The company now has production facilities in the US, Germany, Switzerland and Australia to meet the rising demand. CSL sees China as the next big market as the highly populated country urbanises over the next 20 years. Already it is expanding its Melbourne production facilities to meet the expected demand.

On top of that, CSL will now become the second largest producer of influenza vaccine in the world with its latest acquisition of the vaccine business of multinational pharma company Novartis.

Together, these three reasons make CSL a strong long-term investment opportunity. Healthcare needs will always rise and specialised products will keep CSL in the black for years to come.

Motley Fool contributor Darryl Daté-Shappard does not own shares in any company mentioned.  We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policyThis article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »